Fomepizole as an Adjunct in Severe Acetaminophen Poisoning: Highlighting Its Use in High-Risk Ingestions.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic rationale, preclinical animal studies, and small case series without new clinical trial data.
PubMed 42447326 · doi:10.1097/TME.0000000000000632
What was done
This narrative review synthesized the pathophysiology of acetaminophen-induced hepatotoxicity, the role and limitations of standard N-acetylcysteine therapy, and the mechanism and emerging use of adjunctive fomepizole in severe or high-risk ingestions, alongside considerations for nursing management and monitoring.
What was found
The abstract reports no numerical data or effect sizes. Mechanistically, massive overdoses overwhelm glutathione replenishment by N-acetylcysteine, while fomepizole inhibits CYP2E1 and reduces the conversion of acetaminophen to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). Supporting evidence is derived from animal studies and small human case series, with no large randomized controlled trials available.
Why it matters
Adjunctive fomepizole may provide a complementary mechanism to limit hepatotoxicity in high-risk or massive acetaminophen ingestions where standard N-acetylcysteine therapy alone might be overwhelmed.
Limits
The paper is an unsystematic narrative review. The underlying clinical evidence relies solely on preclinical animal research and small case series, lacking randomized controlled trial data, established clinical endpoints, or standardized administration protocols.
Cited by
- supports N-acetylcysteine is the primary medical treatment for acetaminophen overdose.
- supports Combining acetaminophen with alcohol increases the risk of hepatotoxicity and liver injury.